The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Khemlina G, Ikeda S, Kurzrock R. · 2017

Read The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. by Khemlina G, Ikeda S, Kurzrock R. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5577674.txt.

Description

Khemlina, Ikeda, and Kurzrock review the biology of liver cancer in Molecular Cancer. Hepatocellular carcinoma is the main primary liver cancer. It resists most drug treatment and kills many patients worldwide. New gene maps now show what drives it.

The most common faults hit the TERT promoter, TP53, and CTNNB1. Other frequent changes touch AXIN1, ARID1A, and cell-cycle genes. Patterns split by cause: CTNNB1 with alcohol damage, TP53 with hepatitis B. Key paths cover WNT signals, growth control, and blood-vessel growth. Many faults could be drug targets in principle. Checkpoint immunotherapy helps about a fifth of patients. Some gains last a long time. The authors expect future care to mix immune and matched targeted drugs. Readers get a full gene-to-treatment map.

Catalog record

CREATORKhemlina G, Ikeda S, Kurzrock R.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5577674

Browse the full library · About the Tower of Babel